Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RSV maternal vaccine lot consistency and co-administration with quadrivalent influenza vaccine in healthy non-pregnant women
2021-000357-26Phase 3Suspended
- Sponsor
- GSK
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of RSVPreF3 and Fluarix Quadrivalent in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoint: Solicited administration site events. Started Jun 2021; status: suspended.
02
Drugs
RSVPreF3Fluarix Quadrivalent
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-000357-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000357-26.